EXAS Profile
Exact Sciences Corporation specializes in cancer screening and diagnostic test products, serving a global clientele with innovative medical solutions. Based in Madison, Wisconsin, the company is renowned for its flagship product, Cologuard, a non-invasive stool-based DNA screening test designed to detect biomarkers associated with colorectal cancer and pre-cancerous conditions. This groundbreaking technology provides patients and healthcare providers with a reliable screening option that enhances early detection and treatment outcomes.
In addition to Cologuard, Exact Sciences offers a range of diagnostic tests under the Oncotype brand, including Oncotype DX for breast, prostate, and colon cancers. These gene expression tests provide critical insights into tumor biology, guiding personalized treatment decisions for patients with advanced or recurrent cancers. The company's portfolio also includes the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy test tailored for advanced prostate cancer management, and Oncomap ExTra, which offers comprehensive molecular profiling for rare or aggressive cancer types.
Amidst its innovative product offerings, Exact Sciences has expanded into COVID-19 testing services, leveraging its expertise in molecular diagnostics to support global health initiatives. The company continues to invest in research and development to enhance the performance of its existing products, while also developing new blood and fluid-based tests to further broaden its diagnostic capabilities.
Founded in 1995, Exact Sciences maintains strategic partnerships, including license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc., underscoring its commitment to advancing medical research and clinical diagnostics. With a steadfast focus on improving patient outcomes through early detection and personalized medicine, Exact Sciences remains at the forefront of innovation in cancer screening and diagnostic technologies.
|
